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Abstract 24 
Type II (proteic) toxin-antitoxin (TA) operons are widely spread in bacteria and 25 
archaea. They are organized as operons in which, usually, the antitoxin gene 26 
precedes the cognate toxin gene. The antitoxin is generally acting as a 27 
transcriptional self-repressor, whereas the toxin acts as a co-repressor, both 28 
proteins constituting a harmless complex. When bacteria encounter a stressful 29 
environment, TAs are triggered. The antitoxin protein is unstable and will be 30 
degraded by host proteases, releasing the free toxin to halt essential processes. 31 
The result is a detention of cell growth or even death. Because of their ubiquity 32 
and the essential processes targeted, TAs have been proposed as good 33 
candidates for development of novel antimicrobials. We discuss here the 34 
possible druggability of TAs as antivirals and antibacterials, with focus on the 35 
advantages and the challenges that their use may found in the ‘real’ world. We 36 
present strategies to develop TAs as antibacterials under the light of novel 37 
technologies, such as the use of very small molecules (fragments) as inhibitors 38 
of protein-protein interactions. Appropriate fragments could disrupt the T:A 39 
interfaces leading to the release of the targeted TA pair. Possible ways of 40 
delivery and formulation of TAs are also discussed.  41 
 42 
 43 
Abbreviations: TAs, toxins-antitoxins; WHO, World Health Organization; AbR, Antibiotic 44 
Resistance; FDA, Food and Drug Administration; ICEs, Integrative and Conjugative Elements; 45 
PPI: Protein-Protein Interactions; PSK, post-segregational killing; GMOs, genetically modified 46 
organisms; HIV: human immunodeficiency virus; Tat, transactivator of transcription; TAR, 47 
transactivation response; EDF, Extracellular Death Factor; i-PPIs: inhibitors of PPI; BRET, 48 
Bioluminiscence Resonance Energy Transfer; PNA, Peptide Nucleic Acid 49 
 50 
51 
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Introduction 52 
Humans have long searched for all kind of medicines that could cure their 53 
bodies, restore their health, and prolong their short lifespan. Thereby, search for 54 
a panákeia (pan = all; akés= a cure) as a universal drug that could overcome all 55 
kind of diseases started as early as Medicine itself. Such an ecumenical view 56 
also appears within the tolkienian fantasy, where there was the One Ring of 57 
Power, the One which would rule all the lesser magical rings 58 
(http://www.tolkien.co.uk). Unfortunately, there was no One Ring in real life; 59 
sadly enough to say, a panacea also does not exist, at least for now. Back to 60 
the reality, in this review, we will focus on the present problems of the emerging 61 
antimicrobial-resistance of many pathogenic bacteria and will discuss that there 62 
is an impending need to research on the discovery of novel antimicrobials, to 63 
find alternatives to classical treatments as well as to use novel approaches that 64 
will provide not only one, but multiple solutions to tackle human infections. We 65 
shall discuss the possible druggability of the bacterial toxins-antitoxins (TAs) 66 
family of proteins as well as the pros and cons of these approaches. 67 
 68 
The gloom scenario 69 
Infectious diseases constitute one of the highest causes of deaths of human 70 
beings throughout the world, by the millions every year. The World Health 71 
Organization (WHO: www.who.int/research/ ) stated that “deaths from acute 72 
respiratory infections, diarrhoeal diseases, measles, AIDS, and malaria  73 
account for more than 85% of the mortality from infection worldwide” (WHO 74 
Reports 2010 and 2013). The total amount of children died under 5 years of age 75 
in 2012 summed up to 6.6 million worldwide, and nearly 60% of these deaths 76 
were due to infectious diseases. Pneumonia is the largest single cause of death 77 
in under-fives and about 80% of them could be cured by prevention and proper 78 
antibiotic treatment. These figures apply mostly for the under-developed 79 
countries. In developed countries, albeit the rates of mortality are much lower, 80 
there is high-risk populations formed by children, elderly, and immuno-81 
compromised people, which are generally subjected to antibiotic treatments, 82 
either ambulant or in-hospital. The problem can be much bigger than envisaged 83 
with the appearance of bacteria exhibiting multi- or even pan-drug resistance 84 
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(Falagas & Karageorgopoulos, 2008). Thus the global figures of people 85 
suffering from bacterial infections may reach the hundreds of millions. This 86 
poses huge ethical, medical, and economical concerns that must be tackled in 87 
the most urgent way. One of the main problems found in the everyday practice 88 
of treating these patients is the steady emergence of multidrug-resistant 89 
bacteria. This problem dictates the need for major efforts to discover new 90 
classes of antibacterial drugs. The current portfolio of compounds in clinical 91 
trials includes mostly derivatives of existing antibiotics for which underlying 92 
resistance mechanisms already exist (WHO, Global report on antimicrobial 93 
resistance 2014; 94 
http://www.who.int/drugresistance/documents/surveillancereport/en/). This 95 
scenario is particularly worrisome in the case of hospital infections caused by 96 
highly resistant pathogens, although some advances have been achieved 97 
(Bassetti et al., 2013). Antibiotic-resistance (AbR) is not a new conundrum and 98 
it seems that there is no ultimate denouement but just a temporary regime to 99 
alleviate the problems. The emergence of resistance to the few antibiotics that 100 
are still useful for the treatment of nosocomial infections urges the need for 101 
novel infection prevention and control strategies (Table 1). 102 
 In spite of the fact that AbR compromises our ability to deal with 103 
infectious diseases, a recent report performed in the UK showed that the funds 104 
devoted to this area are small and clearly insufficient (Head et al., 2013). 105 
Furthermore, most large pharmaceutical companies have stopped investing in 106 
new antibiotic research and development: the number of industries working on 107 
active discovery and development programs for antibacterial agents have 108 
dropped in the last 20 years from more than 20 companies to only four in 2013 109 
(Shlaes et al., 2013). In-depth analyses of the Food and Drug Administration 110 
(FDA)-approved antimicrobials have shown that the number of antibacterials 111 
attained a peak by the end of the 1990s and decreased very fast afterwards, 112 
concomitantly with the decline of pharmaceutical companies introducing new 113 
molecules with antibacterial activity into the market (Kinch et al., 2014).  114 
Reasons for this withdrawal include that drug development is a very time-115 
consuming and costly process: from target discovery to lead compound 116 
optimization, followed by preclinical studies and final clinical development and 117 
marketing authorization can take typically more than 10 years. Thus, the pricing 118 
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pressure (mostly due to the marketing of antibiotic generic compounds) and 119 
severe regulatory hurdles have accelerated the withdrawal of companies from 120 
the antibacterial drug market which, in turn, has led to the reduced number of 121 
new drugs approved by the US-FDA. The so-called ‘10 x 20’ initiative, launched 122 
in 2010 to promote the development of 10 new antibiotics by 2020 has resulted, 123 
so far, in only two new molecules, and the number of new drugs in the market is 124 
steadily decreasing, generating a situation that enhances the risks of returning 125 
to the pre-antibiotic era (Boucher et al., 2013). This gloom scenario led to the 126 
proposal of rebooting the FDA’s entire approach to antibiotic development 127 
(Shlaes et al., 2013). In fact, actions in this direction have been taken by the 128 
designation of the Generating Antibiotic Incentives Now (GAIN) program, 129 
included in the FDA Safety and Innovation Act (FDASIA). This gives the FDA, 130 
through the Department of Health and Human Services (HHS), the urgency to 131 
come up with a list of pathogens that qualifying drugs must target and to 132 
develop regulations for the antibiotic incentives (www://bioworld.com). 133 
 134 
Looking for alternatives 135 
Many alternatives to the classical antibiotic treatments have been proposed 136 
(Kaplan & Mason, 1998, Mandell et al., 2007, Imamovic & Sommer, 2013). 137 
There is not a single drug that can cure all infections, and combination of 138 
different therapies seem to be the more convenient, if not the only, approach 139 
especially when development of new antibiotics seems to be still far ahead. We 140 
can envisage some variants of the classical alternatives (Table 2), such as: i) 141 
development of chemical derivatives of the known antibiotics; ii) alternate use of 142 
available antibiotics, and iii) implementation of more biologic approaches like 143 
phage therapy (reviewed in (Deresinski, 2009)), new vaccines, and 144 
antimicrobial peptides. More novel approaches include: i) development of 145 
entirely novel classes of antibiotics; ii) the use of new small molecules as 146 
antivirulence or antipersisters drugs (Conlon et al., 2013); iii) employment of 147 
virulence factors as antibacterials (Marra, 2004), and iv) search for novel targets 148 
(Alonso et al., 2007). The finding that bacteria that have developed resistance 149 
to one antibiotic may display a greater sensitivity to a second one from a distinct 150 
structural class (a phenomenon known as collateral sensitivity) has opened new 151 
and exciting approaches to design antibiotic-treatments (Imamovic & Sommer, 152 
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2013). Furthermore, the identification of virulence genes which are associated 153 
with the bacterial mobilome (plasmids, bacteriophages, and Integrative and 154 
Conjugative Elements, ICEs) has thrown light on mechanism of spread of AbR 155 
among pathogenic bacteria and on how these bacteria are able to evolve very 156 
rapidly as to adapt to new niches and environments (Wellington et al., 2013). It 157 
is clear that the mobilome as a joint bacterial response to the selective pressure 158 
posed by humans plays a central role in the ‘arms race’ between pathogens and 159 
humans. Thus, an interesting strategy that would be worth exploring further was 160 
initiated with the identification of inhibitors that target the transfer of DNA among 161 
bacteria, the so-called conjugation inhibitors, COINS (Fernandez-Lopez et al., 162 
2005).  163 
 Despite all these possible approaches to be developed at a medium-164 
term, the everyday practice in hospitals need protocols to deal with infectious 165 
outbreaks that are easy and reliable to implement. Therefore, in addition to new 166 
antibacterials there is a ne d to develop translational interactions among 167 
healthcare cadres e.g. research rs, hospitals and the companies involved in 168 
drug development. This, in due time, should lead to concepts such as 169 
druglikeness approaches, so that the finding of novel bacterial targets and the 170 
drug development process could be expedited. It is also important to keep in 171 
mind the need to understand the biology of the bacterial species we are aiming, 172 
since biological and, especially, genetic approaches will be a significant aid in 173 
the drug discovery process (Trauner et al., 2014). 174 
Strategies that have been pointed out as potential for drug discovery like 175 
exploiting the bacterial TAs, which seems a promising untapped territory that, 176 
although still constitute controversial unsolved puzzle, merits to be explored 177 
(Alonso et al., 2007, Mutschler & Meinhart, 2011, Gerdes, 2013). In this review, 178 
we will discuss the possible druggability of TAs, which is not as simple as 179 
previously envisaged, but also in terms of choosing the proper toxin (or 180 
combination of two), their delivery, and their targets, because many biologically 181 
active molecules can show a high activity in vitro, but would not reach the 182 
clinical phases due to lack of intestinal absorption and/or poor in vivo metabolic 183 
stability and tissue distribution, the so-called ‘ADME’ (Absorption, Distribution, 184 
Metabolism, and Excretion) properties. 185 
 186 
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Bacterial TAs: What are they? 187 
TAs are usually composed of two genes: the toxin gene encodes a toxin protein 188 
that has toxic effect to the cells, whereas the antitoxin can be either RNA or 189 
protein, which counteracts the toxicity of its cognate toxin. Depending on the 190 
mode of the antitoxin to neutralize the toxin, TAs have been grouped into five 191 
types so far (Fig. 1): i) Type I, the antitoxin antisense RNA prevents translation 192 
of the toxin protein by binding to its complementary toxin mRNA; ii) Type II, the 193 
antitoxin protein binds to the toxin protein through protein-protein interactions 194 
(PPI); iii) Type III, the antitoxin mRNA interacts directly to the toxin protein; iv) 195 
Type IV, the antitoxin protein interferes the binding of the toxin protein to the cell 196 
target, and v) Type V, the antitoxin protein cleaves specifically its cognate toxin 197 
mRNA (Hayes & Van Melderen, 2011, Masuda et al., 2012, Wang et al., 2012).  198 
 We will analyse the potential use of Type II TAs as antimicrobial targets 199 
since they are the most abundant and better studied among TAs, and their 200 
mechanisms of action have been generally unveiled. Type II TAs exhibit typical 201 
features (Fig. 2) such as: i) the antitoxin gene is usually preceding the toxin 202 
gene; ii) both genes are co-transcribed from a promoter located upstream of the 203 
antitoxin gene, and iii) they are translationally coupled. The operon is negatively 204 
autoregulated by the antitoxin upon binding to an operator region that overlaps 205 
the single promoter of the operon, whereas the toxin acts as an efficient co-206 
repressor. The antitoxin protein is labile and more susceptible to degradation by 207 
the host proteases, while the toxin protein is much more stable. The ratio of the 208 
toxin and antitoxin is important to determine the stoichiometry of the TA protein 209 
complex and also to regulate the transcription of the operon, so that the 210 
antitoxin is replenished to shield the toxicity in normal condition (Monti et al., 211 
2007, Cataudella et al., 2012). However, under certain stressful circumstances 212 
such as nutritional stress, colonization of new hosts, DNA-damaging agents, 213 
etc, transcription of the TA will be triggered, and the labile antitoxin will be 214 
degraded more rapidly, unleashing the toxin protein to act on their targets.  215 
The classification of type II TA pairs is not an easy task as the toxin 216 
homologues that share sequence similarities could pair with different antitoxins 217 
with little sequence similarities (e.g. the yefM-yoeB TA genes encode antitoxin 218 
from the Phd family and toxin from the RelE family) (Anantharaman & Aravind, 219 
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2003, Grady & Hayes, 2003, Hayes & Van Melderen, 2011). Toxins that share 220 
similar structures, despite no notable sequence similarities, bind to different 221 
targets (e.g. CcdB binds to DNA gyrase but Kid, which has similar structure as 222 
CcdB, cleaves free mRNAs) (Hargreaves et al., 2002). Further, toxins that were 223 
thought to belong to different families have similar mode of actions (e.g. ParE 224 
and CcdB act on DNA gyrase) (Jiang et al., 2002, van Melderen, 2002). To 225 
complicate the picture more, a toxin might have more than one target: for 226 
instance, toxin MazF-mt6 from Mycobacterium tuberculosis cleaves free mRNA 227 
at the sequence 5′-UU↓CCU-3′ (being ↓ the cleaving site), but also cleaves 23S 228 
rRNA at a single 5’-UUCCU-3’ sequence in the ribosomal A site that contacts 229 
tRNA and ribosome recycling factor (Zhu et al., 2009, Schifano et al., 2013). 230 
Thus, instead of classifying the TA gene pair, 12 toxin superfamilies (Table 3) 231 
and 20 antitoxin superfamilies have been identified (Hayes & Van Melderen, 232 
2011, Leplae et al., 2011) based on sequence similarities. However, the number 233 
of the TA genes that we know up to date seems to be still below the actual 234 
number (Sberro et al., 2013). 235 
 236 
Role of Type II TAs 237 
Several mechanisms of action of the different toxins have been identified (Table 238 
3) via inhibition of replication by targeting the DNA gyrase (e.g. CcdB or ParE) 239 
(Jiang et al., 2002, van Melderen, 2002); inhibition of peptidoglycan synthesis 240 
by phosphorylating the peptidoglycan precursor uridine diphosphate-N-241 
acetylglucosamine (e.g. Zeta/PezT) (Mutschler et al., 2011); and inhibition of 242 
translation by several alternative mechanisms such as: i) cleaving free RNA 243 
(e.g. MazF, Kid/PemK, HicA or MqsR) (Pimentel et al., 2005, Nariya & Inouye, 244 
2008, Jørgensen et al., 2009, Yamaguchi et al., 2009, Agarwal et al., 2010); ii) 245 
cleaving translating RNA (e.g. RelE, YoeB, HigB or YafO) (Christensen et al., 246 
2001, Hurley & Woychik, 2009, Zhang & Inouye, 2009, Zhang et al., 2009); iii) 247 
cleaving tRNAfMet in the anticodon stem-loop (e.g. VapC) (Winther & Gerdes, 248 
2011); iv) inhibiting aminoacyl-tRNA synthetase (e.g. HipA) (Germain et al., 249 
2013), or v) phosphorylating the conserved threonine of the translation 250 
elongation factor EF-Tu (e.g. Doc) (Castro-Roa et al., 2013). The toxic effect 251 
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could be bacteriostatic or bactericidal, depending upon the type of toxin and 252 
time of exposure (Nieto et al., 2010). 253 
 TAs operons can reside on chromosomes, on plasmids, or on both, in 254 
single or multiple copies. In several instances, they are also found within 255 
horizontal mobile elements like pathogenic islands, ICEs, integrative mobilizable 256 
elements, and on large superintegrons (Rowe-Magnus et al., 2003, Szekeres et 257 
al., 2007, Wozniak & Waldor, 2009, Gerdes, 2013). From the beginning of the 258 
discovery of TAs, plasmid-encoded TAs were believed to only function in 259 
exerting post-segregational killing (PSK) of daughter cells that do not inherit the 260 
parental TA-encoded plasmid (Bravo et al., 1987, Bravo et al., 1988, López-261 
Villarejo et al., 2012). However, an additional role of plasmid-encoded TA ccdF 262 
as a transmissible persistence factor was reported (Tripathi et al., 2012), 263 
indicating the role of plasmid-encoded TAs might be far more complex than 264 
envisaged. On the other hand, the functions of the chromosomally-encoded TAs 265 
are even more debatable (van Melderen & Saavedra De Bast, 2009, van 266 
Melderen, 2010, Makarova et al., 2011). They have been suggested to be 267 
involved in at least the following processes: i) global stress response leading to 268 
inhibition of cells growth under unfavourable condition, but the toxicity is 269 
reversible when a normal environment is restored (Christensen et al., 2001); ii) 270 
bacterial programmed cell death, i.e. an altruistic behaviour in which some of 271 
the cells sacrifice themselves to release nutrients for the benefit of the siblings 272 
or community as a whole when nutrients are scarce (Engelberg-Kulka & Glaser, 273 
1999); iii) anti-addiction module: the chromosomally-encoded TAs protect the 274 
cells against PSK mediated by the plasmid-encoded TA homologues (de Bast 275 
et al., 2008); iv) persistence leading to inhibition of cells growth mediated by 276 
TAs to reduce the susceptibility of the cells to antibiotic (Gerdes & 277 
Maisonneuve, 2012); v) biofilm formation as in the case of the antitoxin MqsA of 278 
the MqsA-MqsR TA loci, which serves as a global regulator to repress the 279 
expression of CsgD. This latter protein is the master regulator of biofilm 280 
formation that controls the curli genetic locus and the cellulose production 281 
(Harrison et al., 2009, Soo & Wood, 2013); vi) maintenance of the bacterial 282 
mobilome by stabilization of the dispensable chromosomal regions to prevent 283 
extensive genetic loss (Rowe-Magnus et al., 2003, Szekeres et al., 2007); vii) 284 
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increase survival-rate and virulence (Ren et al., 2012), and viii) colonization of 285 
niches (Norton & Mulvey, 2012). 286 
 287 
TAs as biotechnological tools 288 
Employment of the toxins from TAs to use in a number of biotechnological 289 
applications have been early proposed and, in several cases, successfully 290 
developed for commercial purposes such as positive selection vectors (Stieber 291 
et al., 2008). Applications have been also designed for biological containment of 292 
the controlled release of genetically modified organisms (GMOs), plasmid 293 
stabilization in food production, and protein expression, to name a few. 294 
Excellent reviews on the subject have been published (Suzuki et al., 2005, 295 
Inouye, 2006, Stieber et al., 2008, Unterholzner et al., 2013), and we will make 296 
a brief summary of these topics below. 297 
 298 
Positive selection cloning vectors  299 
The toxicity of protein CcdB from the ccdAB gene pair encoded by plasmid F 300 
was one of the first applications of TAs as biotechnological tools to construct 301 
positive selection vectors, later extended to the kis-kid TA encoded by plasmid 302 
R1. The basis of these plasmid vectors is the expression of the lethal toxin gene 303 
product (such as the bacterial toxins CcdB or Kid), which is counteracted by 304 
expression of the cognate antitoxin (CcdA or Kis, respectively) in trans. When 305 
cloning is desired, transformation of a strain devoid of the antitoxin will result in 306 
selection of recombinants in which only the inactivated toxin gene are recovered 307 
by insertion of the gene of interest within the toxin gene and thus abolishes its 308 
toxicity (Bernard et al., 1994). Employment of the CcdB or Kid toxins has led to 309 
a variety of cloning vectors and strategies, which are excellent positive selection 310 
vectors (Stieber et al., 2008). These cloning systems have been developed 311 
mostly for Escherichia coli but we believe that they might be amenable to be 312 
extended to other bacteria by selection of suitable replicons and appropriate 313 
selectable markers.  314 
 315 
Containment of GMOs 316 
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The controlled release of GMOs into the biosphere has been a subject of 317 
discussion along the years, especially when balancing the benefits versus 318 
possible risks. This is especially true when handling microorganisms because of 319 
the lack of traps to avoid their escape. Attempts to overcome this problem have 320 
led to the development of containment strategies that reduce the risks of 321 
escape of GMOs. These are termed active containment systems which are 322 
based on the controlled expression of lethal genes that would be turned ‘on’ in 323 
the case of escape into the environment. One important problem is the 324 
inactivation of the toxic effect due to mutations. Such is the case of the CcdB 325 
toxin of plasmid F, which targets the bacterial DNA gyrase (Dao-Thi et al., 326 
2005): a single amino acid change can render the hosts resistant to the toxin 327 
(Loris et al., 1999). In this sense, CcdB is an excellent tool for positive-selection 328 
vectors, but it does not seem to be a good candidate for containment purposes. 329 
For these reasons, other toxins with a broader spectrum, such as MazF or Kid, 330 
may be much better candidates. In some cases, combination of two toxins 331 
acting on different targets and controlled by different regulatory signals seem to 332 
be a much better alternative because the risk of escape in these containment 333 
conditions was estimated to be lower than 10-8 (Torres et al., 2003). Further 334 
applications in biosensors and bioremediations, the so-called GeneGuard 335 
system, have been developed within a synthetic biology framework, to be used 336 
in a variety of bacteria (Wright et al., 2014). 337 
 338 
Plasmid stabilization and increasing yield in protein production  339 
One of the problems encountered by industries producing proteins encoded in 340 
plasmids is the probability of plasmid loss due to: toxicity of the product, fitness 341 
of the plasmid-bacteria pair that leads to a higher growth rate of plasmid-free 342 
versus plasmid-carrying cells, and accumulation and selection of mutations 343 
resulting in poor yields, among other problems. In several cases, but not in the 344 
food industry, antibiotic selection must be kept along the fermentation process 345 
which is a costly method and not always attainable. Thus, TAs could be 346 
envisaged as a likely alternative, since PSK is one of the roles of the plasmid-347 
encoded TAs (Gerdes et al., 1986, Hernández-Arriaga et al., 2014). 348 
Construction of plasmid vectors which contain more that one TA will 349 
substantially decrease the number of plasmid-free cells and has proved a useful 350 
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tool to construct vectors to overproduction of plasmid-encoded proteins in the 351 
absence of antibiotic selection (Pecota et al., 1997). Nevertheless, plasmid loss 352 
can occur even under these circumstances. An alternative solution is the 353 
integration of the toxin gene in the chromosome of the bacterial host and 354 
providing the cognate antitoxin from the plasmid expression vector: this 355 
uncoupled stabilization system has shown to be useful in protein production 356 
(Stieber et al., 2008), although it requires special host strains. Another excellent 357 
approach done in Inouye´s lab was by using the codon-specificity of the toxin 358 
MazF, which recognizes and cleaves free mRNA (non-associated to ribosomes) 359 
at the 5’-ACA-3’ codons (Zhang et al., 2003, Suzuki et al., 2005). In this case, 360 
the desired gene is placed under the control of a specific promoter (inducible by 361 
cold), and it is manipulated to change all the ACA codons to protect from self-362 
cleavage. After induction of the MazF toxin, synthesis of proteins is halted due 363 
to cleavage of all mRNAs (except the one encoding the desired protein), but the 364 
cells keep their metabolic functions for several days, so that the only protein to 365 
be synthesized is the desired one (single-protein production). Further, this 366 
method enables the use of cultures grown to higher densities than other 367 
procedures (Suzuki et al., 2007).   368 
 369 
TAs as antivirals 370 
Among the anti-infective drugs recently approved for clinical use, the antiviral 371 
agents have been the more numerous, following a parallel path of that set in the 372 
past by antibiotics. Above 40 antivirals have been licensed, more than half of 373 
them being used in the treatment of human immunodeficiency virus (HIV) 374 
infections. Other antivirals have been licensed for the treatment of infections by 375 
herpes virus, hepatitis (B and C), and influenza. Even for those viral infections 376 
that have already been controlled by therapeutic modalities, search for 377 
additional molecular targets and new treatment strategies still have to be 378 
followed. It is within this context that TAs has offered, probably, the most 379 
promising solutions. 380 
 MazEF is a well-studied TA operon that constitutes an attractive 381 
candidate for antivirals. As mentioned above, MazF toxin is an 382 
endoribonuclease, which preferentially cleaves single-stranded RNA between A 383 
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and C residues at the ACA recognition sequence in a manner independent of 384 
ribosome and thus inhibiting protein synthesis (Zhang et al., 2003), whereas 385 
MazE is its cognate antitoxin which neutralizes MazF toxicity. There have been, 386 
as far as we are aware, a few reports on possible use of MazEF as possible 387 
antivirals (summarized in Fig. 3). The first report contemplates the HIV-encoded 388 
transactivator of transcription (Tat) protein, an early viral regulator, as a possible 389 
target (Chono et al., 2011, Chono et al., 2011). Tat is produced early after HIV-1 390 
infection and binds to the transactivation response (TAR) sequence, inducing 391 
the subsequent expression of other HIV-1 proteins. Thus, a Tat-dependent 392 
MazF expression system of a retroviral vector was constructed in which the 393 
mazF gene was inserted downstream the TAR sequence (Fig. 3a). 394 
Consequently, mazF was to be expressed when the HIV-1 viral Tat protein was 395 
produced and so to cleave the mRNA specifically at ACA codon in the infected 396 
cells. The mazF contains nine ACA sequences, which were engineered to avoid 397 
self-cleavage without altering the amino acid sequence and maintain its toxicity. 398 
On the other hand, the HIV RNA contains more than 240 ACA sequences, and 399 
thus the viral RNAs can hardly escape from the MazF attack. The experiment 400 
was conducted by transducing the recombinant plasmid into human T lymphoid 401 
line CEM-SS cells, which are highly susceptible to HIV infection. Strikingly, 402 
when the transduced cells were infected with HIV-1 IIIB, the replication of the 403 
infected virus was inhibited and the CD4 le el was also not affected (as 404 
described in Fig. 3a). In addition, the level of MazF induced was not enough to 405 
cause serious cell damage and thus maintaining the normal cell growth. Similar 406 
results were observed when the Tat-dependent MazF system were investigated 407 
on rhesus macaque primary CD4+ T cells from monkeys that were infected with 408 
the chimerical virus SHIV 89.6P (Chono et al., 2011, Chono et al., 2011).  409 
 Another line of work made use of a typifying characteristic of viral 410 
proteases, which have very specific cleavage site, to target explicitly the 411 
infected cells instead of the innocent ones (Park et al., 2012). Nonstructural 412 
serine protease, NS3-4A, is a Hepatitis C virus protein that is essential for the 413 
Hepatitis C virus replication. An NS3-activated MazF system was constructed in 414 
which the NS3 protease cleavage site linker was fused in between MazF and 415 
truncated C-terminal of MazE (as we interpret in Fig. 3b). These fusion proteins 416 
are inert, and when incubated with NS3 protease the MazF toxin could be 417 
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activated via cleavage at the linker in between MazE and MazF complex (Park 418 
et al., 2012). Other viral protease cleavage sites worked the same with their 419 
corresponding proteases (HIV-1 protease and factor Xa) (Park et al., 2012). A 420 
similar construct was done by another group which they termed it as ‘zymoxin’ 421 
(Shapira et al., 2012). While this construct was activated by NS3 protease (in 422 
HEK293 T-REx cells that harbour tetracycline-inducible NS3-4A constructs), 423 
NS3-mediated activation of MazF that inhibited cellular protein synthesis was 424 
observed; however, cytotoxic effect was also evident even when NS3 was 425 
mildly induced (Shapira et al., 2012). The possible undesirable effects of MazF 426 
cleaving the eukaryotic mRNAs could be avoided by careful control of the 427 
dosage of the toxin, so that MazF was able to cleave the viral, but not the cell, 428 
mRNAs (Chono et al., 2011).  429 
 430 
Type II TAs as targets for antibacterial drug development 431 
One of the most challenging aspects in drug discovery is to find novel chemical 432 
or biological molecules that may act as antibacterials. The discovery pipeline 433 
includes new natural products or products that result from new biosynthetic 434 
pathways (e.g. molecules that control cell communication), although they also 435 
may include novel chemical molecules or antibacterial protein/peptides. 436 
Potential targets for the development of novel antimicrobials could be the toxins 437 
of the bacterial TA genes, partly because they are widely distributed in bacteria 438 
and archaea but not in eukaryotic cells (Inouye, 2006, Alonso et al., 2007, 439 
Hayes, 2011, Makarova et al., 2011, Mutschler & Meinhart, 2011, Chan et al., 440 
2012). Some toxin homologues were also identified in silico in fungi, but their 441 
functionality has not been experimentally validated, and it is also unknown 442 
whether the cognate antitoxins are present. Obligate intracellular organisms are 443 
devoid of, or have less, TA cassettes but, in contrast, free-living slow growing 444 
prokaryotes have many TA cassettes (Pandey & Gerdes, 2005).  445 
 Comparative genomic studies showed that the presence of TA modules 446 
is significantly associated with the pathogenicity of bacteria (De la Cruz et al., 447 
2013). For example, M. tuberculosis contains at least 30 functional TA genes 448 
(88 putative TA gene pairs were tested) (Ramage et al., 2009), whereas its non-449 
pathogenic counterpart, M. smegmatis has only three functional TA genes 450 
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(Robson et al., 2009, McKenzie et al., 2012). Furthermore, the number of TA 451 
genes reported so far can be a serious underestimation of the real figures in the 452 
microbial world. A more thorough way to identify functional TA genes, instead of 453 
in silico screening, was done via shotgun cloning which had revealed that many 454 
toxin genes could only be cloned when the neighbouring antitoxin genes were 455 
present (Sberro et al., 2013).  The above features make the exploitation of 456 
TAs as antibacterials a major challenge: due to their redundancy, target 457 
validation as well as the specificity and selectivity (off-target activity) of any drug 458 
candidate targeting a specific TA would be very difficult to assess. Despite of 459 
that, the toxins of the TA-pairs could be an attractive antibacterial targets to be 460 
used as stand-alone drugs or in combination with classical antibiotics 461 
(Mutschler & Meinhart, 2011, Park et al., 2013, Unterholzner et al., 2013). 462 
However, it seems that the combination with current approved antibiotics would 463 
have, at least at present, another major challenge in terms of matching the 464 
formulation to generate a combination product. 465 
 The route to approach these problems can vary depending upon the way 466 
the toxin effect is envisaged. In the first place, if the toxin is going to be the 467 
candidate itself, then the fact that TAs are absent in human is irrelevant. The 468 
toxins of the TA pairs, as all novel targets to be considered for drug discovery 469 
must comply with a set of requirements, such as lack of toxicity to eukaryotic 470 
cells and target only the infecting bacteria. However, the toxins of TA genes are 471 
also harmful to the human cells unless there is a careful monitoring of the toxin 472 
dosage (as mentioned above on the antiviral tests) and safe delivery systems 473 
are applied, in addition to provision for the replenishment of commensal flora. If, 474 
however, the TA is going to be used as a target for drug ligands, then all of the 475 
above arguments are relevant, keeping in mind the challenges related to 476 
redundancy. The presence of more than one copy of the same TA may be a 477 
source on uncertainty because closely related antitoxins may functionally 478 
interact with each other (Zhu et al., 2010). Several strategies to disrupt the 479 
interface between antitoxins and their cognate toxins by inhibitors of PPI have 480 
been envisaged as well as the possible use of the toxins in combined strategies 481 
(Alonso et al., 2007, Mutschler & Meinhart, 2011). We will summarize below 482 
some of the reported studies as well as our views on whether employment of 483 
TAs could be considered as promising candidates for future use in the 484 
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biopharmaceutical industry. We will also discuss the pros and cons of the use of 485 
these toxins as druggable antimicrobial targets. 486 
 487 
Toxicity to eukaryotic cells 488 
Most of the known toxins from TAs act as endoribonucleases that cleave 489 
mRNAs associated or not to translating ribosomes, regardless mRNAs from 490 
prokaryotes or eukaryotes. Thus, the toxin could act as an antitumoural agent 491 
and, in fact, it was proposed that the Kid toxin from plasmid R1 could be used 492 
as an efficient anti-cancer compound (de la Cueva Méndez et al., 2003). More 493 
recently, reversion of induced-solid tumours in mice has been reported by 494 
employment of an engineered version of the MazF toxin; nevertheless, the rate 495 
of success in reversion was around 50%, probably due to loss of functional 496 
toxin (Shimazu et al., 2014). Such a loss of activity was not observed for toxins 497 
VapC from M. tuberculosis or PasB from plasmid pTF-FC2 Thiobacillus 498 
ferrooxidans when expressed into human cancer cells (Wieteska et al., 2014). 499 
These findings leave an open door to test more thoroughly the possibilities of 500 
employment of toxins into tumoural cells. However, under the light of possible 501 
use of toxins as antibacterials, it is important to consider that if the toxins have 502 
to be delivered directly to the patients to kill the pathogens, the adverse effect of 503 
the toxins on the normal commensal flora and the human cells could also be 504 
difficult to avoid. Perhaps, as shown the antiviral activity of the MazF 505 
interferase, the dosage of the toxin is a critical factor when testing its activity on 506 
eukaryotic cells (Chono et al., 2011, Chono et al., 2011). More elegant 507 
approaches would include the more specific targeting of the pathogens, or the 508 
bacteria that harbour TAs by triggering the release of the toxins, which are not 509 
found in human cells.  510 
    511 
Effect on the infecting bacteria 512 
Some toxins are bactericidal, as it should be for an ‘ideal’ antibacterial, so that 513 
the infecting bacteria would be killed by the toxin (Zielenkiewicz & Ceglowski, 514 
2005, Mutschler & Meinhart, 2011). However, stasis and dormancy due to 515 
temporal reduction of the cell growth is a more common effect of the toxin, and 516 
this bacteriostatic effect can be reversed by induction of the antitoxin (Pedersen 517 
et al., 2002, Maisonneuve et al., 2011, Germain et al., 2013). Recovery of the 518 
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dormancy due to the toxin may be only effective during a given time-period, and 519 
prolonged exposure of the bacteria to a toxin like RelE can lead to cell lethality 520 
(Nieto et al., 2006). In addition, there are also some other factors to be 521 
considered if toxin alone is the one to be administered, since there are 522 
instances in which the toxin may have a different panorama of toxicity in 523 
different hosts, e.g. expression of toxin Zeta of plasmid pSM19035, which was 524 
discovered in Streptococcus pyogenes, is bactericidal for the gram-positive 525 
Bacillus subtilis and bacteriostatic for the gram-negative E. coli (Zielenkiewicz & 526 
Ceglowski, 2005). 527 
 528 
Disruption of TA complex by inhibitors of PPIs (i-PPIs)  529 
One of the proposed approaches to the druggability of bacterial toxins is to 530 
identify peptides or small molecules that are able to disrupt the TA interaction 531 
based on their binding interface (PPI-approaches (Labbé et al., 2013)). The 532 
binding affinities of the TA pair varies making it difficult to estimate the dosage 533 
of the inhibitors: for instance the PezAT pair exhibited very strong binding 534 
affinities (binding constant in the femtomolar range), which is three to eight 535 
orders of magnitude higher than other TAs such as Phd-Doc, RelBE, CcdAB 536 
and even Epsilon-Zeta, which is a homologue of PezAT (Gazit & Sauer, 1999, 537 
Camacho et al., 2002, Dao-Thi et al., 2005, Overgaard et al., 2009, Mutschler et 538 
al., 2010). Even though PPI interfaces are very interesting targets to develop 539 
novel molecules, there are still not promising examples of drugs designed 540 
against TA interfaces. The use of high-throughput screening techniques to 541 
identify hits that act as i-PPIs in conjunction with the development of techniques 542 
to optimize the possible hits to discover proper leads (hit-to-lead techniques) is 543 
a matter not fully solved yet. 544 
 A specific Bioluminiscence Resonance Energy Transfer (BRET) assay 545 
(Xu et al., 1999) to test libraries of peptides that could disrupt the T:A interfaces 546 
was developed (Nieto et al., 2006). This tool is an in vivo assay, amenable for 547 
high-throughput scaling up, and with clear advantages over Fluorescence 548 
Resonance Energy Transfer (FRET)-based assays because BRET is not 549 
susceptible to photo-bleaching, and thus yields more reliable results. BRET has 550 
been proven to be a constructive tool to identify potential hits for T:A interruption 551 
(Fig. 4) (Lioy et al., 2010). In this study, several libraries encompassing various 552 
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millions of peptides were used to try to disrupt the Epsilon-Zeta TA protein 553 
complex. Two positive 17 amino acid long hits were found in two sublibraries, 554 
however, no new records on further progresses have been reported (Lioy et al., 555 
2010). It also remains unknown whether the peptides were binding to the 556 
antitoxin or to the toxin. Besides disruption of the interfaces of both proteins, it is 557 
important to ensure that the binding of the peptides, if to the toxin, does not 558 
hinder the catalytic activity of the toxin, so that the released toxin can still act on 559 
its target to kill the pathogens. As shown in another study, peptides designed 560 
based on antitoxin sequences were able to disrupt the T:A interface, but the 561 
toxicity of the toxin was also reduced (Agarwal et al., 2010), we suggest 562 
peptides designed based on toxin sequence to bind to antitoxin would be a 563 
better approach. Employment of peptides of sizes ranging from 6 to 60 amino 564 
acids to tackle disruption of PPIs has important advantages such as high 565 
specificity and, potentially lower failure rates after its inclusion into the drug 566 
pipeline of clinical trials. However, biological molecules have shown several 567 
shortcomings, such as poor oral availability and high costs of bioprocessing.  568 
 Alternatively to traditional high-throughput screening of libraries, 569 
fragment-based methods for drug discovery (Erlanson et al., 2004) has 570 
emerged as a stunning approach and mainstream for the discovery of new 571 
drugs within most pharmaceutical companies and many academic groups (Fig. 572 
5). Comparison of putative candidates for no el drugs indicated that drugs 573 
derived from fragment-based screens could uncover novel compounds with 574 
more drug-like properties than those derived from more conventional drug 575 
discovery techniques. The search of these fragments is driven by the Rule of 576 
Three: molecular mass <300 Da, the number of hydrogen bond donors and 577 
acceptors each ≤3 and the clogP ≤3 (Congreve et al., 2003). The fragment-578 
based lead discovery deals with low-molecular-mass and low-affinity molecules, 579 
so that later on they can be optimized into drug leads (Park et al., 2013). This 580 
fragment-based approach has been very successful since it has allowed the 581 
marketing of a drug, vemurafenib (a drug for metastatic melanoma), in only 582 
six years (Baker, 2013)). In addition, several groups in the UK have joined to 583 
develop the 3D Fragment Consortium (http://www.3DFrag.org) devoted to the 584 
building of a shared library (500-3000 fragments) with enhanced three-585 
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dimensionality of compounds that seem to be more advantageous than the 586 
traditional approach.  587 
 New technologies aimed at characterization of the contact surface 588 
between two interacting proteins, in conjunction to methodologies based on 589 
structure-based design, have facilitated the detection of small molecules that 590 
act as i-PPIs. The identification of compounds that may act as i-PPIs seems to 591 
be attainable by computational drug design (Bienstock, 2012). There are a 592 
number of strategies that have been employed to check for hotspot regions in 593 
the protein-protein interfaces, such as protein crystallography to elucidate the 594 
3D-protein structure, molecular docking, virtual screening and approaches to 595 
design novel drug libraries (reviewed in depth by (Bienstock, 2012, Huang, 596 
2014)), although there is a strong need to have curated databases to help in the 597 
discovery of PPI-modulators (see, for instance: http://www.vls3d.com/). 598 
Development of novel databases to assist the finding and design of novel i-PPIs 599 
should prove to be useful for these purposes (Labbé et al., 2013). A number of 600 
TA structures have been solved, which would lead to a more thorough approach 601 
to find small molecules that are able to disrupt the T:A interactions, which 602 
should be especially designed since hydrophobic residues seem to dominate 603 
the interfaces between the toxin and its cognate antitoxin (Loris et al., 1999, 604 
Hargreaves et al., 2002, Kamada et al., 2003, Takagi et al., 2005, Kamphuis et 605 
al., 2007, Oberer et al., 2007, Kumar et al., 2008, Brown et al., 2009, Francuski 606 
& Saenger, 2009, Miallau et al., 2009, Arbing et al., 2010, Dienemann et al., 607 
2011, Bøggild et al., 2012, Heaton et al., 2012, Kwon et al., 2012, Feng et al., 608 
2013, Samson et al., 2013, Schureck et al., 2013). Structural knowledge on TAs 609 
should enable us to get a better understanding on the surface contacts between 610 
the two protein pairs so that development of inhibitors is facilitated (Park et al., 611 
2013). These approaches could be refined by employment of selected 612 
databases dedicated to PPIs that have already known inhibitors, so that small 613 
molecules can be taken as examples to construct guidelines to characterize i-614 
PPIs (http://2p2idb.cnrs-mrs.fr).  615 
 616 
Other strategies leading to toxin druggability 617 
A number of different strategies have been suggested as possible means to the 618 
druggability of toxins (Mutschler & Meinhart, 2011, Chan et al., 2013, Gerdes, 619 
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2013, Unterholzner et al., 2013). These strategies are based on the finding that 620 
the antitoxin is more susceptible to degradation by the host proteases than its 621 
cognate toxin. Therefore by inhibiting the replenishment of the antitoxin, the 622 
toxin will be released and can exhibit its toxicity to the cells while its cognate 623 
antitoxin is degraded. We can conceive a number of strategies, all having their 624 
pros and cons, as schematized in Fig. 6.  625 
 Firstly, one approach could be the inhibition of transcription of the TA 626 
pair so that auto-regulation would not take place and synthesis of the TA would 627 
be hindered. By use of the different half-lives of the two proteins, the likelihood 628 
of degradation of the antitoxin and release of the toxin could be increased. How 629 
to achieve this goal? One possibility could be the use of a mutant of the 630 
antitoxin with enhanced DNA binding affinity (‘super-repressor’) but devoid of 631 
the ability to complex to its cognate toxin. This could be achieved as usually the 632 
binding site of the antitoxin to the DNA is at the N-terminal moiety whereas to its 633 
cognate toxin is at the C-terminus. Perhaps the challenge would be the binding 634 
affinity, as antitoxin is known as a weak repressor. Characterization of these 635 
features could be easily followed by a novel technique based on differential 636 
repression of the Green Fluorescent Protein expression (Chan et al., 2014).637 
 Secondly, we could envisage the inhibition of translation of the antitoxin 638 
by antisense molecules. Even though both antitoxin and toxin genes are co-639 
transcribed as a single mRNA transcript, the toxin gene usually carries its own 640 
Shine-Dalgarno sequence that is embedded within its upstream antitoxin gene 641 
(Chan et al., 2012). Thus, silencing of the antitoxin could be achieved by the 642 
binding of short RNA sequences (or specific oligonucleotides) to the antitoxin 643 
coding region or to the initiation of translation signals of the antitoxin, without 644 
affecting translation of the toxin. However a few factors have to be considered, 645 
such as the efficiency of the antisense to bind to the mRNA, the length of the 646 
antisense molecule, possible interference of the translation of the toxin protein, 647 
the stability of the antisense molecule and also the double-stranded RNA after 648 
binding to the mRNA target. One of the valuable approaches discovered in 649 
these recent years is the employment of the Peptide Nucleic Acid (PNA) 650 
technology (Nielsen & Egholm, 1999). PNA molecules are synthetic analogues 651 
of nucleic acids in which the phosphate-sugar backbone is replaced by a 652 
flexible pseudo-peptide polymer to which the bases are attached. Thus, PNA 653 
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can mimic and pair to DNA or RNA generating duplexes that are resistant to 654 
enzymatic degradation. Although PNA has been proven as good silencer, 655 
delivery would be one of the major challenges that are not easy to tackle (see 656 
below).   657 
 A third approach could be to target the proteases that cleave the 658 
antitoxin, which appears to be either Lon or ClpP (Van Melderen et al., 1996, 659 
Christensen et al., 2004), although there may be other not yet identified 660 
proteases. Induction of the proteases would lead to antitoxin degradation and 661 
release of the cognate toxin. Activation of proteases that degrade the antitoxins 662 
can lead to killing of bacterial persisters by the freed toxin (Williams & 663 
Hergenrother, 2012); this approach, in combination to antibiotics, resulted in 664 
biofilm eradication in vitro. We consider that this could be a novel avenue to 665 
treatment chronic infectious diseases (Conlon et al., 2013), like endocarditis, 666 
bronchitis, otitis, etc, or to tackle diseases that derive from the infection of 667 
internal prosthesis or catheter-related interventions 668 
(http://www.cdc.gov/hicpac/bsi/bsi-guidelines-2011.html).  669 
 Another interesting strategy, developed for the mazEF TA (a 670 
widespread TA among many bacteria, many of them pathogenic) has been 671 
proposed (Kumar & Engelberg-Kulka, 2014). This involves triggering of the TA 672 
from without by the so-called Extracellular Death Factor (EDF), a short peptide 673 
that acts as a quorum sensor. Although EDF is species-specific, it seems that 674 
they can provoke triggering of mazEF in heterologous hosts: the Pseudomonas 675 
aeruginosa or the B. subtilis EDF can activate the E. coli mazEF, leading to 676 
death of the latter bacterial cells (Kumar et al., 2013). This clever strategy might 677 
be enough as a starting point to develop a novel antibacterial that, however, 678 
would activate only this particular TA (Kumar & Engelberg-Kulka, 2014). 679 
 Last but not least, since different TAs have different targets, selection 680 
of more than a kind of TAs could be an alternative to explore: the combined use 681 
of TAs that target cell walls (e.g. PezAT) with those that target mRNAs (MazEF) 682 
could lead to an antibacterial with more broad spectrum.  683 
 However, even if any of the above approaches could be followed (and 684 
some of them merit a deeper exploration), we believe that they would confront a 685 
major problem, which is the delivery strategies. 686 
 687 
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Drug delivery  688 
One of the hurdles to overcome in designing new drugs is how to deliver them 689 
to the appropriate tissue target. Research in drug delivery is multidisciplinary, 690 
requiring knowledge of: i) how drugs work, ii) their chemical and physical 691 
properties, iii) how these properties affect the in vivo behaviour of the drugs, iv) 692 
how these drugs reach their targets, and vi) what could be done to formulate 693 
these drugs to potentially solve any delivery problems associated with them. 694 
Therefore, drug delivery research necessitates interdisciplinary collaborations 695 
both at a national and international level. Although a range of delivery systems 696 
is available, the delivery of sensitive drugs such as peptides, nucleic acid based 697 
therapeutics (including antisense RNA and small interfering RNAs), simple and 698 
complex carbohydrates, and synthetic vaccines presents a major challenge to 699 
the pharmaceutical industry. Formulation for novel molecules is very costly, 700 
since nearly 10% of the costs of drug development are devoted to drug delivery 701 
(Allen & P.R., 2012). Some of the abovementioned biologics could be 702 
formulated in ways that can be expensive or inconvenient: for instance, 703 
replacement of powders with ready-to-use liquids may be an important 704 
improvement, but storage of the material (cold versus shelf storage) may 705 
constitute an important bias against employment of proteins, so that improving 706 
heat stability will lead to simpler transportation and distribution processes. 707 
 New developments in drug delivery research are likely to have enormous 708 
economic impacts upon the pharmaceutical and biotechnology industries. In 709 
fact, drug delivery research represents a US$70 billion a year industry. Centres 710 
for Drug Delivery and Formulation have been established all over the world to 711 
promote research, development and training in drug delivery science. There has 712 
also been a focus on realizing the commercial potential of innovative molecules 713 
(e.g. peptides, nucleic acid based therapies and vaccines) or delivery 714 
technologies that are developed from the basic research centres. Thus it is no 715 
wonder that a number of novel clever approaches have been proposed to 716 
deliver new drugs, as it had to be the case if bacterial toxins are going to be 717 
developed as antimicrobials. One interesting system, albeit still hypothetical, 718 
could be the employment of bacterial minicells for delivery (Fig. 7; (de la Cueva-719 
Méndez, 2013)). Minicells are produced by bacteria defective in cell division; 720 
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they lack chromosomal DNA, but plasmids do segregate into them and continue 721 
to be metabolically active. Thus, as early shown in many laboratories, ours 722 
among them (Espinosa et al., 1984, Lacks et al., 1986), plasmids in minicells 723 
are able to synthesize de novo the products they encode, including TA proteins, 724 
as shown for the kis-kid pair (Bravo et al., 1987, Bravo et al., 1988). Plasmids 725 
encoding the desired TA construction will segregate into the minicells, making 726 
them good delivery candidates to the targeted cells (MacDiarmid et al., 2007). 727 
However, while minicells could be envisaged as useful delivery solutions to 728 
treatment of cancer cells (MacDiarmid et al., 2007, de la Cueva-Méndez, 2013), 729 
they do not seem to be appropriate enough to treatment of bacterial infections 730 
as minicells will not be engulfed by prokaryotic cells. It is worth pointing that 731 
delivery of toxins as antibacterials should be done intracellularly, since they kill 732 
the pathogenic bacteria from within.  733 
 A more elegant strategy is the use of recombinant bacteriophages, 734 
defective for lysis and harbouring the desired toxin gene cloned under the 735 
control of an early (usually very strong) promoter. Upon injection of the phage 736 
DNA, the toxin gene will be transcribed and translated, releasing the toxin which 737 
will kill the pathogens (Huys et al., 2013, Samson et al., 2013). Another 738 
interesting possibility is to make use of cell-penetrating peptides (Sebbage, 739 
2009). This approach would seem more appropriate to use the toxins as 740 
antivirals (Chono et al., 2011) than antibacterials because of these peptides 741 
would not overcome the barrier offered by the bacterial cell wall. We could 742 
imagine that coupling the toxins to microcins peptides (lasso peptides; 743 
(Rebuffat, 2012)) that penetrate the bacterial cell wall might offer an alternative 744 
to employment of cell penetrating peptides.   745 
 746 
Conclusions and final thoughts 747 
We have presented here a number of plausible, and sometimes, speculative, 748 
approaches to tackle the druggability of TAs. We have also tried to discuss 749 
different angles on the subject as well as to present it in a thought-provoking 750 
manner. Fortunately, an increasing number of protein TA structures are being 751 
solved, which will facilitate the study of the TA-interfaces. This, in turn, will 752 
permit to perform in silico docking experiments to design molecules that may 753 
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disrupt the T:A interactions. In our opinion, a fragment-based drug design to 754 
deal with the disruption of the TAs interactions seems to be one of the most 755 
likely approaches to develop TAs as good candidates to enter into the 756 
antibacterials pipeline. Perhaps the most useful approach would be: i) rationale 757 
design of the fragments library based on the known structures of the TAs solved 758 
so far (Park et al., 2013), and ii) employment of fragments designed to bind to 759 
the C-terminal moiety of the antitoxin, which seems to be less structured than 760 
the N-terminal domain (the appropriateness of the chemical space between the 761 
two proteins).  An exciting alternative to explore is the employment of antisense 762 
small RNAs as the molecules to inhibit the translation of the operon (Ji et al., 763 
1999, Faridani et al., 2006, Makarova et al., 2006, Kawano et al., 2007, Mruk & 764 
Kobayashi, 2013) in combination to an appropriate delivery system, perhaps 765 
engineered bacteriophages or peptides. 766 
 However, and before there is a good proof of principle on the 767 
druggability of the TAs proteins as effective antibacterials, other approaches 768 
could be envisaged. One of them would be to diagnose first several of the TAs 769 
encoded by the infecting bacterium through PCR-amplification using sets of 770 
specific oligonucleotides per each TA pair. Identification of a set (or of all) TAs 771 
could be easily achieved by entering into an appropriate database like, for 772 
instance, TADB (http://bioinfo-mml.sjtu.edu.cn/TADB/). This could be followed 773 
by administration of the most indicated drug for the identified infecting agent 774 
rather than a random drug use (and perhaps abuse). 775 
 All in all, we believe that research on new antibacterials should meet 776 
the needs of the day-to-day clinicians working in hospitals, where fast 777 
responses should be granted within easy technological access to user-friendly 778 
databases. If we could conceive such a scenario, then novel avenues will open 779 
to explore real novel drugs.  780 
 781 
Acknowledgements 782 
Thanks are due to Marc Lemonnier for critical reading of the manuscript and 783 
helpful comments. Research financed by the Spanish Ministry of Economy and 784 
Innovation, grant CSD-2008/00013 (INTERMODS, to M.E.). 785 
 786 
Competing interests statement  787 
Page 25 of 52
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 25
The authors declare no competing financial interests. 788 
 789 
References 790 
Agarwal S, Mishra NK, Bhatnagar S & Bhatnagar R (2010) PemK toxin of Bacillus 791 
anthracis is a ribonuclease. J Biol Chem 285: 7254-7270. 792 
Alonso JC, Balsa D, Cherny I, et al. (2007) Bacterial toxin-antitoxin systems as targets 793 
for the development of novel antibiotics. Enzyme-mediated resistance to 794 
antibiotics: mechanisms, dissemination, and prospects for inhibition (Bonomo 795 
RA & Tolmasky ME, eds.), pp. 313-329. ASM Press, Washington, DC. 796 
Allen TM & P.R. C (2012) Drug delivery systems: entering the mainstream. Science 797 
303: 1818-1821. 798 
Anantharaman V & Aravind L (2003) New connections in the prokaryotic toxin-antitoxin 799 
network: relationship with the eukaryotic nonsense-mediated RNA decay 800 
system. Genome Biol 4: R81. 801 
Arbing MA, Handelman SK, Kuzin AP, et al. (2010) Crystal structures of Phd-Doc, 802 
HigA, and YeeU establish multiple evolutionary links between microbial growth-803 
regulating toxin-antitoxin systems. Structure 18: 996-1010. 804 
Baker M (2013) Fragment-based lead discovery grows up. Nat Rev Drug Discov 12: 5-805 
7. 806 
Bassetti M, Merelli M, Temperoni C & Astilean A (2013) New antibiotics for bad bugs: 807 
where are we? Annals Clin Microbiol Antimicrob 12: 22-37. 808 
Bernard P, Gabant P, Bahassi EM & Couturier M (1994) Positive-selection vectors 809 
using the F plasmid ccdB killer gene. Gene 148: 71-74. 810 
Bienstock RJ (2012) Computational drug design targeting protein–protein interactions. 811 
Curr Pharm Des 18: 1240-1254. 812 
Bøggild A, Sofos N, Andersen KR, Feddersen A, Easter AD, Passmore LA & 813 
Brodersen DE (2012) The crystal structure of the intact Escherichia coli RelBE 814 
toxin-antitoxin complex provides the structural basis for conditional 815 
cooperativity. Structure 20: 1641-1648. 816 
Boucher HW, Talbot GH, Benjamin DK, Bradley J, Guidos RJ, Jones RN, Murray BE, 817 
Bonomo RA, Gilbert D & for the Infectious Diseases Society of America (2013) 818 
10 × '20 progress--Development of new drugs active against Gram-negative 819 
Bacilli: an update from the Infectious Diseases Society of America. Clin Infect 820 
Dis 56: 1685-1694. 821 
Page 26 of 52
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 26
Bravo A, de Torrontegui G & Díaz R (1987) Identification of components of a new 822 
stability system of plasmid R1, Par D, that is close to the origin of replication of 823 
this plasmid. Mol Gen Genet 210: 101-110. 824 
Bravo A, Ortega S, de Torrontegui G & Díaz R (1988) Killing of Escherichia coli cells 825 
modulated by components of the stability system ParD of plasmid R1. Mol Gen 826 
Genet 215: 146-151. 827 
Brown BL, Grigoriu S, Kim Y, Arruda JM, Davenport A, Wood TK, Peti W & Page R 828 
(2009) Three dimensional structure of the MqsR:MqsA complex: a novel TA pair 829 
comprised of a toxin homologous to RelE and an antitoxin with unique 830 
properties. PLoS Pathog 5: e1000706. 831 
Camacho AG, Misselwitz R, Behlke J, Ayora S, Welfle K, Meinhart A, Lara B, Saenger 832 
W, Welfle H & Alonso JC (2002) In vitro and in vivo stability of the epsilon2zeta2 833 
protein complex of the broad host-range Streptococcus pyogenes pSM19035 834 
addiction system. Biol Chem 383: 1701-1713. 835 
Castro-Roa D, Garcia-Pino A, De Gieter S, van Nuland NAJ, Loris R & Zenkin N (2013) 836 
The Fic protein Doc uses an inverted substrate to phosphorylate and inactivate 837 
EF-Tu. Nat Chem Biol 9: 811–817. 838 
Cataudella I, Trusina A, Sneppen K, Gerdes K & Mitarai N (2012) Conditional 839 
cooperativity in toxin–antitoxin regulation prevents random toxin activation and 840 
promotes fast translational recovery. Nucleic Acids Res 40: 6424-6434. 841 
Congreve M, Carr R, Murray C & Jhoti H (2003) A ‘Rule of Three’ for fragment-based 842 
lead discovery? Drug Discov Today 8: 876-877. 843 
Conlon BP, Nakayasu ES, Fleck LE, LaFleur MD, Isabella VM, Coleman K, Leonard 844 
SN, Smith RD, Adkins JN & Lewis K (2013) Activated ClpP kills persisters and 845 
eradicates a chronic biofilm infection. Nature 503: 365-370. 846 
Chan WT, Moreno-Córdoba I, Yeo CC & Espinosa M (2012) Toxin-antitoxin genes of 847 
the gram-positive pathogen Streptococcus pneumoniae: so few and yet so 848 
many. Microbiol Mol Biol Rev 76: 773-791. 849 
Chan WT, Moreno-Córdoba I, Yeo CC & Espinosa M (2013) Toxin-antitoxin loci in 850 
Streptococcus pneumoniae. Prokaryotic toxin-antitoxins (Gerdes K, ed.), pp. 851 
315-339. Springer-Verlag Berlin Heidelberg, Berlin. 852 
Chan WT, Yeo CC, Sadowy E & Espinosa M (2014) Functional validation of putative 853 
toxin-antitoxin genes from the Gram-positive pathogen Streptococcus 854 
pneumoniae: phd-doc is the fourth bona-fide operon. Frontiers in Microbiology 855 
(in press). 856 
Chono H, Saito N, Tsuda H, Shibata H, Ageyama N, Terao K, Yasutomi Y, Mineno J & 857 
Kato I (2011) In vivo safety and persistence of endoribonuclease gene-858 
Page 27 of 52
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 27
transduced CD4+ T cells in cynomolgus macaques for HIV-1 gene therapy 859 
model. PLoS One 6: e23585. 860 
Chono H, Matsumoto K, Tsuda H, et al. (2011) Acquisition of HIV-1 resistance in T 861 
lymphocytes using an ACA-specific Escherichia coli mRNA interferase. Hum 862 
Gene Ther 22: 35-43. 863 
Christensen KS, Maenhauf-Michel G, Mine N, Gothesman S, Gerdes K & Van 864 
Melderen L (2004) Overproduction of the Lon protease triggers inhibition of 865 
translation in Escherichia coli: involvement of the yefM-yoeB toxin-antitoxin 866 
system. Mol Microbiol 51: 1705-1717. 867 
Christensen SK, Mikkelsen M, Pedersen K & Gerdes K (2001) RelE, a global inhibitor 868 
of translation, is activated during nutritional stress. Proc Natl Acad Sci USA 98: 869 
14328-14333. 870 
Dao-Thi MH, Van Melderen L, De Genst E, Afif H, Buts L, Lode W & Loris R (2005) 871 
Molecular basis of gyrase poisoning by the addiction toxin CcdB. J Mol Biol 348: 872 
1091–1102. 873 
Davies J & Davies D (2010) Origins and evolution of antibiotic resistance. Microbiol Mol 874 
Biol Rev 74: 417-433. 875 
de Bast MS, Mine N & van Melderen L (2008) Chromosomal toxin-antitoxin systems 876 
may act as antiaddiction modules. J Bacteriol 190: 4603-4609. 877 
De la Cruz MA, Zhao W, Farenc C, Gimenez G, Raoult D, Cambillau C, Gorvel JP & 878 
Méresse S (2013) A toxin-antitoxin module of Salmonella promotes virulence in 879 
mice. PLoS Pathog 9: e1003827. 880 
de la Cueva-Méndez G (2013) Systems and methods for diminishing cell growth and 881 
including selective killing of target cells. Vol. EP 2570134 A1 (Council MR, ed.), 882 
pp. UK. 883 
de la Cueva Méndez G, Mills AD, Clay Farrace L, Diaz-Orejas R & Laskey RA (2003) 884 
Regulatable killing of eukaryotic cells by the prokaryotic proteins Kid and Kis. 885 
EMBO J 22: 246-251. 886 
Deresinski S (2009) Bacteriophage therapy: exploiting smaller fleas. Clin Infect Dis 48: 887 
1096–1101. 888 
Dienemann C, Bøggild A, Winther KS, Gerdes K & Brodersen DE (2011) Crystal 889 
structure of the VapBC toxin–antitoxin complex from Shigella flexneri reveals a 890 
hetero-octameric DNA-binding assembly. J Mol Biol 414: 713-722. 891 
Engelberg-Kulka H & Glaser G (1999) Addiction modules and programmed cell death 892 
and antideath in bacterial cultures. Annu Rev Microbiol 53: 43-70. 893 
Erlanson DA, McDowell RS & O’Brien T (2004) Fragment-based drug discovery. J Med 894 
Chem 47: 3463-3482. 895 
Page 28 of 52
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 28
Espinosa M, Lopez P & Lacks SA (1984) Transfer and expression of recombinant 896 
plasmids carrying pneumococcal mal genes in Bacillus subtilis. Gene 28: 301-897 
310. 898 
Falagas ME & Karageorgopoulos DE (2008) Pandrug resistance (PDR), extensive drug 899 
resistance (XDR), and multidrug resistance (MDR) among Gram-negative 900 
bacilli: Need for international harmonization in terminology. Clin Infect Dis 46: 901 
1121-1122. 902 
Faridani OR, Nikravesh A, Pandey DP, Gerdes K & Good L (2006) Competitive 903 
inhibition of natural antisense Sok-RNA interactions activates Hok-mediated cell 904 
killing in Escherichia coli. Nucleic Acids Res 34: 5915-5922. 905 
Feng S, Chen Y, Kamada K, Wang HH, Tang K, Wang M & Gao Y-G (2013) YoeB–906 
ribosome structure: a canonical RNase that requires the ribosome for its 907 
specific activity. Nucleic Acids Res 41: 9549-9556. 908 
Fernandez-Lopez R, Machon C, Longshaw CM, Martin S, Molin S, Zechner EL, 909 
Espinosa M, Lanka E & de la Cruz, F (2005) Unsaturated fatty acids are 910 
inhibitors of bacterial conjugation. Microbiology 151: 3517-3526. 911 
Francuski D & Saenger W (2009) Crystal structure of the antitoxin-toxin protein 912 
complex RelB-RelE from Methanococcus jannaschii. J Mol Biol 393: 898-908. 913 
Gazit E & Sauer RT (1999) Stability and DNA binding of the Phd protein of the phage 914 
P1 plasmid addiction system. J Biol Chem 274: 2652-2657. 915 
Gerdes K (2013) Introduction. Prokaryotic toxin-antitoxins (Gerdes K, ed.), pp. 315-916 
339. Springer-Verlag Berlin Heidelberg, Berlin. 917 
Gerdes K & Maisonneuve E (2012) Bacterial persistence and toxin-antitoxin loci. Annu 918 
Rev Microbiol 66: 103-123. 919 
Gerdes K, Bech FW, Jørgensen ST, Løbner-Olesen A, Rasmussen PB, Atlung T, Boe 920 
L, Karlstrom O, Molin S & von Meyenburg K (1986) Mechanism of 921 
postsegregational killing by the hok gene product of the parB system of plasmid 922 
R1 and its homology with the relF gene product of the Escherichia coli relB 923 
operon. EMBO J 5: 2023-2029. 924 
Germain E, Castro-Roa D, Zenkin N & Gerdes K (2013) Molecular mechanism of 925 
bacterial persistence by HipA. Mol Cell 52: 248-254. 926 
Grady R & Hayes F (2003) Axe-Txe, a broad-spectrum proteic toxin-antitoxin system 927 
by a multidrug-resistant, clinical isolate of Enterococcus faecium. Mol Microbiol 928 
47: 1419-1432. 929 
Hargreaves D, Santos-Sierra S, Giraldo R, Sabariegos-Jareño R, de la Cueva-Méndez 930 
G, Boelens R, Díaz-Orejas R & Rafferty JB (2002) Structural and functional 931 
Page 29 of 52
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 29
analysis of the Kid toxin protein from Esherichia coli plasmid R1. Structure 10: 932 
1425-1433. 933 
Harrison JJ, Wade WD, Akierman S, Vacchi-Suzzi C, Stremick CA, Turner RJ & Ceri H 934 
(2009) The chromosomal toxin yafQ is a determinant of multidrug tolerance for 935 
Escherichia coli growing in a biofilm. Antimicrob Agents Chemother 53: 2253-936 
2258. 937 
Hayes F (2011) Moving in for the kill: activation of an endoribonuclease toxin by a 938 
quorum-sensing peptide. Mol Cell 41: 617-618. 939 
Hayes F & Van Melderen L (2011) Toxins-antitoxins: diversity, evolution and function. 940 
Crit Rev Biochem Mol Biol 46: 386-408. 941 
Head MG, Fitchett JR, Cooke MK, Wurie FB, Atun R, Hayward AC, Holmes A, Johnson 942 
AP & Woodford N (2013) Systematic analysis of funding awarded for 943 
antimicrobial resistance research to institutions in the UK, 1997–2010. J 944 
Antimicrob Chemother 69: 548-554.. 945 
Heaton BE, Herrou J, Blackwell AE, Wysocki VH & Crosson S (2012) Molecular 946 
structure and function of the novel BrnT/BrnA toxin-antitoxin system of Brucella 947 
abortus. J Biol Chem 287: 12098-12110. 948 
Hernández-Arriaga AM, Chan WT, Espinosa M & Díaz-Orejas R (2014) Conditional 949 
activation of toxin-antitoxin systems: postsegregational killing and beyond. 950 
Microbiol Spectrum 2: PLAS-0009-2013. 951 
Huang S-Y (2014) Search strategies and evaluation in protein–protein docking: 952 
principles, advances and challenges. Drug Discov Today 19: 1081-1096. 953 
Hurley JM & Woychik NA (2009) Bacterial toxin HigB associates with ribosomes and 954 
mediates translation-dependent mRNA cleavage at A-rich sites. J Biol Chem 955 
284: 18605-18613. 956 
Huys I, Pirnay JP, Lavigne R, Jennes S, de Vos D, Casteels M & Verbeken G (2013) 957 
Paving a regulatory pathway for phage therapy. EMBO Rep 14: 951-954. 958 
Imamovic L & Sommer MOA (2013) Use of collateral sensitivity networks to design 959 
drug cycling protocols that avoid resistance development. Science Translational 960 
Medicine 5: 204ra132. 961 
Inouye M (2006) The discovery of mRNA interferases: implication in bacterial 962 
physiology and application to biotechnology. J Cell Physiol 209: 670-676. 963 
Ji Y, Marra A, Rosenberg M & Woodnutt G (1999) Regulated antisense RNA eliminates 964 
alpha-toxin virulence in Staphylococcus aureus infection. J Bacteriol 181: 6585-965 
6590. 966 
Page 30 of 52
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 30
Jiang Y, Pogliano J, Helinski DR & Konieczny I (2002) ParE toxin encoded by the 967 
broad-host-range plasmid RK2 is an inhibitor of Escherichia coli gyrase. Mol 968 
Microbiol 44: 971-979. 969 
Jørgensen MG, Pandey DP, Jaskolska M & Gerdes K (2009) HicA of Escherichia coli 970 
defines a novel family of translation-independent mRNA interferases in bacteria 971 
and archaea. J Bacteriol 191: 1191-1199. 972 
Kamada K, Hanaoka F & Burley SK (2003) Crystal structure of the MazE/MazF 973 
complex: molecular bases of antidote-toxin recognition. Mol Cell 11: 875-884. 974 
Kamphuis MB, Monti MC, van den Heuvel RHH, Lopez-Villarejo J, Diaz-Orejas R & 975 
Boelens R (2007) Structure and function of bacterial Kid-Kis and related toxin-976 
antitoxin systems. Protein Pept Lett 14: 113-124  977 
Kaplan SL & Mason EO jr. (1998) Management of infections due to antibiotic-resistant 978 
Streptococcus pneumoniae. Clin Microbiol Rev 11: 628-644. 979 
Kawano M, Aravind L & Storz G (2007) An antisense RNA controls synthesis of an 980 
SOS-induced toxin evolved from an antitoxin. Mol Microbiol 64: 738-754. 981 
Kinch MS, Patridge E, Plummer M & Hoyer D (2014) An analysis of FDA-approved 982 
drugs for infectious disease: antibacterial agents Drug Discov Today 19: 1283-983 
1287. 984 
Kumar P, Issac B, Dodson EJ, Turkenburg JP & Mande SC (2008) Crystal structure of 985 
Mycobacterium tuberculosis YefM antitoxin reveals that it is not an intrinsically 986 
unstructured protein. J Mol Biol 383: 482-493. 987 
Kumar S & Engelberg-Kulka H (2014) Quorum sensing peptides mediating interspecies 988 
bacterial cell death as a novel class of antimicrobial agents. Curr Opin Microbiol 989 
21: 22-27. 990 
Kumar S, Kolodkin-Gal I & Engelberg-Kulka H (2013) Novel quorum-sensing peptides 991 
mediating interspecies bacterial cell death. mBio 4: e00314-00313. 992 
Kwon A-R, Kim J-H, Park SJ, Lee K-Y, Min Y-H, Im H, Lee I, Lee K-Y & Lee B-J (2012) 993 
Structural and biochemical characterization of HP0315 from Helicobacter pylori 994 
as a VapD protein with an endoribonuclease activity. Nucleic Acids Res 40: 995 
4216-28. 996 
Labbé CM, Laconde G, Kuenemann MA, Villoutreix BO & Sperandio O (2013) iPPI-DB: 997 
a manually curated and interactive database of small non-peptide inhibitors of 998 
protein–protein interactions. Drug Discov Today 18: 958-968. 999 
Lacks SA, López P, Greenberg B & Espinosa M (1986) Identification and analysis of 1000 
genes for tetracycline resistance and replication functions in the broad-host-1001 
range plasmid pLS1. J Mol Biol 192: 753-765. 1002 
Page 31 of 52
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 31
Leplae R, Geeraerts D, Hallez R, Guglielmini J, Drèze P & Van Melderen L (2011) 1003 
Diversity of bacterial type II toxin–antitoxin systems: a comprehensive search 1004 
and functional analysis of novel families. Nucleic Acids Res 39: 5513-5525. 1005 
Lioy VS, Rey O, Balsa D, Pellicer T & Alonso JC (2010) A toxin-antitoxin module as a 1006 
target for antimicrobial development Plasmid 63: 31-39. 1007 
López-Villarejo J, E. D-N, Hernández-Arriaga AM & Díaz-Orejas R (2012) Kis antitoxin 1008 
couples plasmid R1 replication and parD (kis, kid) maintenance modules. 1009 
Plasmid 67: 118-127. 1010 
Loris R, Dao Thi M-H, Bahassi L, Van Melderen L, Poortmans F, Liddington R, 1011 
Couturier M & Wyns L (1999) Crystal structure of CcdB, a topoisomerase 1012 
poison from E. coli. J Mol Biol 285: 1667-1677. 1013 
MacDiarmid JA, Mugridge NB, Weiss JC, et al. (2007) Bacterially derived 400 nm 1014 
particles for encapsulation and cancer cell targeting of chemotherapeutics. 1015 
Cancer Cell 11: 431-445. 1016 
Maisonneuve E, Shakespeare LJ, Jørgensen MG & Gerdes K (2011) Bacterial 1017 
persistence by RNA endonucleases. Proc Natl Acad Sci U S A 108: 13206-1018 
13211. 1019 
Makarova KS, Grishin NV & Koonin EV (2006) The HicAB cassette, a putative novel, 1020 
RNA-targeting toxin-antitoxin system in archaea and bacteria. Bioinformatics 1021 
22: 2581-2584. 1022 
Makarova KS, Wolf YI, Snir S & Koonin EV (2011) Defense islands in bacterial and 1023 
archaeal genomes and prediction of novel defense systems. J Bacteriol 193: 1024 
6039-6056. 1025 
Mandell LA, Wunderink RG, Anzueto A, et al. (2007) Infectious Diseases Society of 1026 
America/American Thoracic Society consensus guidelines on the management 1027 
of community-acquired pneumonia in adults. Clin Infect Dis 44: S27-72. 1028 
Marra A (2004) Can virulence factors be viable antibacterial targets? Expert Rev Anti 1029 
Infect Ther 2: 61-72. 1030 
Masuda H, Tan Q, Awano N, Wu K-P & Inouye M (2012) YeeU enhances the bundling 1031 
of cytoskeltal polymers of MreB and FtsZ, antagonizing the CbtA (YeeV) toxicity 1032 
in Escherichia coli. Mol Microbiol 84: 979-989. 1033 
McKenzie JL, Robson J, Berney M, Smith TC, Ruthe A, Gardner PP, Arcus VL & Cook 1034 
GM (2012) A VapBC toxin-antitoxin module is a post-transcriptional regulator of 1035 
metabolic flux in Mycobacteria. J Bacteriol 194: 2189-2204. 1036 
Miallau L, Faller M, Chiang J, Arbing M, Guo F, Cascio D & Eisenberg D (2009) 1037 
Structure and proposed activity of a member of the VapBC family of toxin-1038 
Page 32 of 52
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 32
antitoxin systems. VapBC-5 from Mycobacterium tuberculosis. J Biol Chem 284: 1039 
276-283. 1040 
Monti MC, Hernandez-Arriaga AM, Kamphuis MB, Lopez-Villarejo J, Heck AJR, 1041 
Boelens R, Diaz-Orejas R & van den Heuvel RHH (2007) Interactions of Kid-Kis 1042 
toxin-antitoxin complexes with the parD operator-promoter region of plasmid R1 1043 
are piloted by the Kis antitoxin and tuned by the stoichiometry of Kid-Kis 1044 
oligomers. Nucleic Acids Res 35: 1737-1749. 1045 
Mruk I & Kobayashi I (2013) To be or not to be: regulation of restriction–modification 1046 
systems and other toxin–antitoxin systems. Nucleic Acids Res 42: 70-86. 1047 
Mutschler H & Meinhart A (2011) ε/ζ systems: their role in resistance, virulence, and 1048 
their potential for antibiotic development. J Mol Med 89: 1183-1194. 1049 
Mutschler H, Reinstein J & Meinhart A (2010) Assembly dynamics and stability of the 1050 
pneumococcal Epsilon Zeta antitoxin toxin (PezAT) system from Streptococcus 1051 
pneumoniae. J Biol Chem 285: 21797-21806. 1052 
Mutschler H, Gebhardt M, Shoeman RL & Meinhart A (2011) A novel mechanism of 1053 
programmed cell death in bacteria by toxin-antitoxin systems corrupts 1054 
peptidoglycan synthesis. PLoS Biol 9: e1001033. 1055 
Nariya H & Inouye M (2008) MazF, an mRNA interferase, mediates programmed cell 1056 
death during multicellular Myxococcus development. Cell 132: 55-66. 1057 
Nielsen PE & Egholm M (1999) An introduction to Peptide Nucleic Acid. Current Issues 1058 
Molec Biol 1: 89-104. 1059 
Nieto C, Sadowy E, de la Campa AG, Hryniewicz W & Espinosa M (2010) The 1060 
relBE2Spn toxin-antitoxin system of Streptococcus pneumoniae: role in 1061 
antibiotic tolerance and functional conservation in clinical isolates. PLoS One 5: 1062 
e11289. 1063 
Nieto C, Pellicer T, Balsa D, Christensen SK, Gerdes K & Espinosa M (2006) The 1064 
chromosomal relBE2 toxin-antitoxin locus of Streptococcus pneumoniae: 1065 
characterization and use of a bioluminescence resonance energy transfer assay 1066 
to detect toxin-antitoxin interaction. Mol Microbiol 59: 1280-1296. 1067 
Norton JP & Mulvey MA (2012) Toxin-antitoxin systems are important for niche-specific 1068 
colonization and stress resistance of uropathogenic Escherichia coli. PLoS 1069 
Pathog 8: e1002954. 1070 
Oberer M, Zangger K, Gruber K & Keller W (2007) The solution structure of ParD, the 1071 
antidote of the ParDE toxin antitoxin module, provides the structural basis for 1072 
DNA and toxin binding. Protein Sci 16: 1676-1688. 1073 
Page 33 of 52
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 33
Overgaard M, Borch J & Gerdes K (2009) RelB and RelE of Escherichia coli form a 1074 
tight complex that represses transcription via the ribbon-helix-helix motif in 1075 
RelB. J Mol Biol 394: 183-196. 1076 
Pandey DP & Gerdes K (2005) Toxin-antitoxin loci are highly abundant in free-living but 1077 
lost from host-associated prokaryotes. Nucleic Acids Res 33: 966-976. 1078 
Park J-H, Yamaguchi Y & Inouye M (2012) Intramolecular regulation of the sequence-1079 
specific mRNA interferase activity of MazF fused to a MazE fragment with a 1080 
linker cleavable by specific proteases. Appl Environ Microbiol 78: 3794-3799. 1081 
Park S, Mann J & Li N (2013) Targeted inhibitor design: lessons from small molecule 1082 
drug design, directed evolution, and vaccine research Chem Eng Process Tech 1083 
1: 1004. 1084 
Park SJ, Son WS & Lee B-J (2013) Structural overview of toxin–antitoxin systems in 1085 
infectious bacteria: A target for developing antimicrobial agents. Biochim 1086 
Biophys Acta - Proteins and Proteomics 1834: 1155-1167. 1087 
Pecota DC, Kim CS, Wu K, Gerdes K & Wood TK (1997) Combining the hok/sok, 1088 
parDE, and pnd, postsegregational killer loci to enhance plasmid stability. Appl 1089 
Environ Microbiol 63: 1917-1924. 1090 
Pedersen K, Christensen KS & Gerdes K (2002) Rapid induction and reversal of a 1091 
bacteriostatic conditions by controlled expression of toxins and antitoxins. Mol 1092 
Microbiol 45: 501-510. 1093 
Pimentel B, Madine MA & de la Cueva-Mendez G (2005) Kid cleaves specific mRNAs 1094 
at UUACU sites to rescue the copy number of plasmid R1. EMBO J 24: 3459-1095 
3469. 1096 
Ramage HR, Connolly LE & Cox JS (2009) Comprehensive functional analysis of 1097 
Mycobacterium tuberculosis toxin-antitoxin systems: implications for 1098 
pathogenesis, stress responses, and evolution. PLoS Genet 5: e1000767. 1099 
Rebuffat S (2012) Microcins in action: amazing defence strategies of Enterobacteria. 1100 
Biochem Soc Trans 40: 1456–1462. 1101 
Ren D, Walker A & Daines DA (2012) Toxin-antitoxin loci vapBC-1 and vapXD 1102 
contribute to survival and virulence in nontypeable Haemophilus influenzae. 1103 
BMC Microbiol 12: 263. 1104 
Robson J, McKenzie JL, Cursons R, Cook GM & Arcus VL (2009) The vapBC Operon 1105 
from Mycobacterium smegmatis is an autoregulated toxin-antitoxin module that 1106 
controls growth via inhibition of translation J Mol Biol 390: 353-367. 1107 
Rowe-Magnus DA, Guerout AM, Biskri L, Bouige P & Mazel D (2003) Comparative 1108 
analysis of superintegrons: engineering extensive genetic diversity in the 1109 
Vibrionaceae. Genome Res 13: 428-442. 1110 
Page 34 of 52
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 34
Samson JE, Magadán AH, Sabri M & Moineau S (2013) Revenge of the phages: 1111 
defeating bacterial defences. Nature Rev Microbiol 11: 675-687. 1112 
Samson JE, Spinelli S, Cambillau C & Moineau S (2013) Structure and activity of AbiQ, 1113 
a lactococcal endoribonuclease belonging to the type III toxin–antitoxin system. 1114 
Mol Microbiol 87: 756-768. 1115 
Sberro H, Leavitt A, Kiro R, Koh E, Peleg Y, Qimron U & Sorek R (2013) Discovery of 1116 
functional toxin/antitoxin systems in bacteria by shotgun cloning. Mol Cell 50: 1117 
136-148. 1118 
Schifano JM, Edifor R, Sharp JD, Ouyang M, Konkimalla A, Husson RN & Woychik NA 1119 
(2013) Mycobacterial toxin MazF-mt6 inhibits translation through cleavage of 1120 
23S rRNA at the ribosomal A site. Proc Natl Acad Sci U S A 110: 8501-8506. 1121 
Schureck MA, Maehigashi T, Miles SJ, Marquez J, Ei Cho S, Erdman R & Dunham CM 1122 
(2013) Structure of the Proteus vulgaris HigB-(HigA)2-HigB toxin-antitoxin 1123 
complex. J Biol Chem. 289: 1060-1070. 1124 
Sebbage V (2009) Cell-penetrating peptides and their therapeutic applications. 1125 
Bioscience Horizons 2: 64-72. 1126 
Shapira A, Shapira S, Gal-Tanamy M, Zemel R, Tur-Kaspa R & Benhar I (2012) 1127 
Removal of hepatitis C virus-infected cells by a zymogenized bacterial toxin. 1128 
PLoS One 7: e32320. 1129 
Shimazu T, Mirochnitchenko O, Phadtare S & Inouye M (2014) Regression of solid 1130 
tumors by induction of MazF, a bacterial mRNA endoribonuclease. J Mol 1131 
Microbiol Biotechnol 24: 228-233. 1132 
Shlaes DM, Sahm D, Opiela C & Spellberg B (2013) The FDA reboot of antibiotic 1133 
development. Antimicrob Agents Chemother 57: 4605-4607. 1134 
Soo VW & Wood TK (2013) Antitoxin MqsA represses curli formation through the 1135 
master biofilm regulator CsgD. Sci Rep 3: 3186. 1136 
Stieber D, Gabant P & Szpirer CY (2008) The art of selective killing: plasmid 1137 
toxin/antitoxin systems and their technological applications. BioTechniques 45: 1138 
344-346. 1139 
Suzuki M, Mao L & Inouye M (2007) Single protein production (SPP) system in 1140 
Escherichia coli. Nat Protocols 2: 1802-1810. 1141 
Suzuki M, Zhang J, Liu M, Woychik NA & Inouye M (2005) Single protein production in 1142 
living cells facilitated by an mRNA interferase. Mol Cell 18: 253-261. 1143 
Szekeres S, Dauti M, Wilde C, Mazel D & Rowe-Magnus DA (2007) Chromosomal 1144 
toxin-antitoxin loci can diminish large-scale genome reductions in the absence 1145 
of selection. Mol Microbiol 63: 1588-1605. 1146 
Page 35 of 52
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 35
Takagi H, Kakuta Y, Okada T, Yao M, Tanaka I & Kimura M (2005) Crystal structure of 1147 
archaeal toxin-antitoxin RelE-RelB complex with implications for toxin activity 1148 
and antitoxin effects. Nat Struct Mol Biol 12: 327-331. 1149 
Torres B, Jaenecke S, Timmis KN, García JL & Díaz E (2003) A dual lethal system to 1150 
enhance containment of recombinant micro-organisms. Microbiology 149: 3595-1151 
3601. 1152 
Trauner A, Sassetti CM & Rubin EJ (2014) Genetic strategies for identifying new drug 1153 
targets. Microbiology Spectrum 2: MGM2-0030-2013. 1154 
Tripathi A, Dewan PC, Barua B & Varadarajan R (2012) Additional role for the ccd 1155 
operon of F-plasmid as a transmissible persistence factor. Proc Natl Acad Sci U 1156 
S A 109: 12497-12502. 1157 
Unterholzner SJ, Poppenberger B & Rozhon W (2013) Toxin–antitoxin systems: 1158 
Biology, identification, and application. Mob Genet Elements 3: e26219. 1159 
van Melderen L (2002) Molecular interactions of the CcdB poison with its bacterial 1160 
target, the DNA gyrase. Int J Med Microbiol 291: 537-544. 1161 
van Melderen L (2010) Toxin-antitoxin systems: why so many, what for? Curr Opin 1162 
Microbiol 13: 781-785. 1163 
van Melderen L & Saavedra De Bast M (2009) Bacterial toxin–antitoxin systems: more 1164 
than selfish entities? PLoS Genet 5: e1000437. 1165 
Van Melderen L, Dao Thi M-H, Lecchi P, Gottesman S, Couturier M & Maurizi MR 1166 
(1996) ATP-dependent degradation of CcdA by Lon protease. Effects of 1167 
secondary structure and heterologous subunit interactions. J Biol Chem 271: 1168 
27730-27738. 1169 
Walsh CT, Fischer SL, Park I-S, Prahalad M & Wu Z (1996) Bacterial resistance to 1170 
vancomycin: five genes and one missing hydrogen bond tell the story. Current 1171 
Biology 3: 21-28. 1172 
Wang X, Lord DM, Cheng H-Y, et al. (2012) A new type V toxin-antitoxin system where 1173 
mRNA for toxin GhoT is cleaved by antitoxin GhoS. Nat Chem Biol 8: 855-861. 1174 
Wellington EM, Boxall AB, Cross P, et al. (2013) The role of the natural environment in 1175 
the emergence of antibiotic resistance in Gram-negative bacteria. Lancet Infect 1176 
Dis 13: 155-165. 1177 
Wieteska Ł, Skulimowski A, Cybula M & Szemraj J (2014) Toxins VapC and PasB from 1178 
prokaryotic TA modules remain active in mammalian cancer cells. Toxins 6: 1179 
2948-2961. 1180 
Williams JJ & Hergenrother PJ (2012) Artificial activation of toxin-antitoxin systems as 1181 
an antibacterial strategy. Trends Microbiol 20: 291-298. 1182 
Page 36 of 52
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 36
Winther KS & Gerdes K (2011) Enteric virulence associated protein VapC inhibits 1183 
translation by cleavage of initiator tRNA. Proc Natl Acad Sci U S A 108: 7403–1184 
7407. 1185 
Wozniak RAF & Waldor MK (2009) A toxin–antitoxin system promotes the maintenance 1186 
of an integrative conjugative element. PLoS Genet 5: e1000439. 1187 
Wright O, Delmans M, Stan GB & Ellis T (2014) GeneGuard: a modular plasmid 1188 
system designed for biosafety. ACS Synth Biol DOI: 10.1021/sb500234s. 1189 
Xu Y, Piston DW & Johnson CH (1999) A bioluminescence resonance energy transfer 1190 
(BRET) system: application to interaction circadian clock proteins. Proc Natl 1191 
Acad Sci U S A 96: 151-156. 1192 
Yamaguchi Y, Park J-H & Inouye M (2009) MqsR, a crucial regulator for quorum 1193 
sensing and biofilm formation, is a GCU-specific mRNA interferase in 1194 
Escherichia coli. J Biol Chem 284: 28746-28753. 1195 
Zhang Y & Inouye M (2009) The inhibitory mechanism of protein synthesis by YoeB, an 1196 
Escherichia coli toxin. J Biol Chem 284: 6627-6638. 1197 
Zhang Y, Yamaguchi Y & Inouye M (2009) Characterization of YafO, an Escherichia 1198 
coli toxin. J Biol Chem 284: 25522-25531. 1199 
Zhang Y, Zhang J, Hoeflich KP, Ikura M & Inouye M (2003) MazF cleaves cellular 1200 
mRNAs specifically at ACA to block protein synthesis in Escherichia coli. Mol 1201 
Cell 12: 913-923. 1202 
Zhu L, Sharp JD, Kobayashi H, Woychik NA & Inouye M (2010) Noncognate 1203 
Mycobacterium tuberculosis toxin-antitoxins can physically and functionally 1204 
interact. J Biol Chem 285: 39732-39738. 1205 
Zhu L, Inoue K, Yoshizumi S, Kobayashi H, Zhang Y, Ouyang M, Kato F, Sugai M & 1206 
Inouye M (2009) Staphylococcus aureus MazF specifically cleaves a pentad 1207 
sequence, UACAU, which is unusually abundant in the mRNA for pathogenic 1208 
adhesive factor SraP. J Bacteriol 191: 3248-3255. 1209 
Zielenkiewicz U & Ceglowski P (2005) The toxin-antitoxin system of the streptococcal 1210 
plasmid pSM19035. J Bacteriol 187: 6094-6105. 1211 
 1212 
 1213 
1214 
Page 37 of 52
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 37
Legends to the figures 1215 
Fig. 1. The five types of TAs. TAs have been categorized into five types so far, 1216 
depending on the nature of antitoxins and on the mechanisms by which the 1217 
antitoxins sequester their cognate toxins. Toxins are always proteins whereas 1218 
antitoxins can be RNAs (Type I and III) or proteins (Type II, IV and IV). Type I: 1219 
the antitoxin antisense-RNA binds to its complementary toxin mRNA to prevent 1220 
toxin translation. Type II: TA genes encode both toxin and antitoxin proteins that 1221 
bind strongly to each other to form an inert complex. Type III: the antitoxin is an 1222 
mRNA with a stretch of repeated motifs which binds to its cognate toxin protein 1223 
and thus hinders its toxicity. Type IV: the antitoxin protein acts as the antagonist 1224 
to its cognate toxin to bind to the cell target. Finally, in Type V, the antitoxin 1225 
protein is an endoribonuclease that cleaves its cognate toxin mRNA.    1226 
 1227 
Fig. 2. Features of Type II TAs. Like other TA types, Type II TAs consists of two 1228 
genes organized as an operon. The antitoxin gene precedes the toxin one. Both 1229 
genes usually overlap and are co-transcribed from one or two promoters. TA 1230 
genes encode both antitoxin and toxin proteins that bind to each other and 1231 
generate a harmless complex under normal conditions. The antitoxin protein 1232 
also binds to its own promoter to negatively autoregulate the TA operon. The 1233 
toxin protein is not able to bind to the promoter by itself, but serves as a co-1234 
repressor upon binding of the antitoxin to the promoter, to further repress 1235 
transcription of the operon. Under stressful circumstances, the antitoxin protein 1236 
which is more labile, is degraded more rapidly by the host proteases and thus 1237 
liberate the toxin protein to act on the cell target. 1238 
  1239 
Fig. 3. Conceptual models of potential approaches using TA as antivirals. (a) 1240 
Activation of engineered viral promoter-MazF by early viral regulator protein. 1241 
HIV-encoded transactivator of transcription (Tat) protein is an early viral 1242 
regulator that binds to transactivation response (TAR) sequence. A Tat-1243 
dependent MazF toxin expression system of a retroviral vector was designed in 1244 
which the mazF gene was inserted downstream the TAR sequence. MazF is an 1245 
endoribonulease that cleaves free mRNA at the ACA codons. The mazF gene 1246 
was engineered to avoid self-cleavage by changing the base sequences but 1247 
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conserving its amino acid sequence to preserve its toxicity to cleave the viral 1248 
mRNAs. The vector was then transduced into human T lymphoid line CEM-SS 1249 
cells. When HIV-1 attempts to enter the cell, interactions between cell surface 1250 
molecules and viral envelope proteins allow the envelope to fuse with the cell 1251 
membrane and subsequently viral RNA genome is released to the cell (1). The 1252 
viral single-strand RNA genome is transcribed into double-strand DNA (2), and 1253 
then integrated into a host chromosome (3). The proviral genome can 1254 
consequently be transcribed into viral mRNA (4) for translation into HIV 1255 
proteins. The early viral protein Tat will bind to the TAR sequence to induce 1256 
MazF production (5) to cleave viral mRNAs (6). It is worth to mention that this 1257 
system will only be triggered in the HIV-1-infected cells but not the innocent 1258 
ones. (b) Cleavage of specific linker by viral protease to trigger MazF. NS3-4A 1259 
is an HCV protein that has a very specific cleavage site. A recombinant vector 1260 
was constructed in which the NS3 protease cleavage site linker was fused in 1261 
between MazF and truncated C-terminal of MazE. Once the HCV enters the 1262 
hepatocyte (1), HCV will take over parts of the intracellular machinery to 1263 
replicate (2). NS3-4A will be produced and cleave specifically to the MazEF-1264 
linker (3) and thus liberating MazF to cleave viral mRNAs (4). 1265 
 1266 
Fig. 4. Detection of disruption of TA protein complex by i-PPI via BRET assays. 1267 
The BRET assay technology is based on the efficient resonance energy transfer 1268 
between a bioluminescent donor moiety and a fluorescent acceptor moiety. The 1269 
bioluminescent Renilla luciferase (RLUC) that was fused with toxin protein 1270 
catalyses the coelenterazine substrate to coelenteramide with concomitant light 1271 
emission at 480 nm. When the acceptor enhanced yellow fluorescent protein 1272 
(EYFP)-antitoxin is in close proximity to RLUC, EYPF will absorb the energy 1273 
emitted by the RLUC/coelenterazine reaction and emit yellow light that can be 1274 
measured at 530 nm. If the interactions between the toxin and antitoxin proteins 1275 
are disrupted by i-PPI, RLUC and EYFP will be too far apart for resonance 1276 
energy transfer and only the blue-emitting spectrum of RLUC will be detected.  1277 
 1278 
Fig. 5. Combination of combinatorial chemistry with high-throughput has 1279 
contributed to the development of large screening libraries of compounds. 1280 
However, the largest imaginable collection of compounds falls short of potential 1281 
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chemical diversity space. As molecular size decreases, the number of possible 1282 
molecules decreases exponentially. Thus, at least from a theoretical point of 1283 
view, it would result easier to screen large collections of very small molecules 1284 
(“fragments”) and, later on proceed to expand, merge, or link them. Fragment 1285 
screening is an excellent method for the identification and validation of lead 1286 
compounds that can later on be tested for development of therapeutic agents. 1287 
Fragments are small (MW <300Da) and can provide the sampling of chemical 1288 
space more effectively than other screening methods. Highly ligand efficient hits 1289 
have been identified for several soluble proteins and for i-PPIs purposes. 1290 
Determination of the three-dimensional structure of the target proteins in 1291 
conjunction to compounds with a greater degree of 3D shape is a good method 1292 
to increase the diversity of libraries. Finally, through different rounds of chemical 1293 
modifications and/or combination with other molecules, fragments with 1294 
increased affinity for the target protein can be developed.  1295 
 1296 
Fig. 6. Proposed strategies to us  TA as antimicrobials. A few approaches have 1297 
been suggested to make use of the toxin of the pathogen itself for self-killing: 1298 
Inhibition of TA transcription (I) or inhibition of antitoxin translation (II), thus 1299 
antitoxin cannot be replenished and once the remaining antitoxin is degraded, 1300 
the toxin will be free to act on the bacterial cell; Activation of host proteases (III) 1301 
to rapidly degrade the labile antitoxin proteins and disruption of TA protein 1302 
complex by i-PPI (IV) to liberate the toxin, as well as triggering activation of TA 1303 
by quorum sensors (V). 1304 
 1305 
Fig. 7. What are minicells? Bacterial cells that harbour mutations in some of 1306 
their genes involved in cell division (like min mutants in E. coli or divIV mutants 1307 
in B. subtilis) were shown to have a septum abnormally positioned, resulting in 1308 
a cell of normal size and a minicell. Because of their small size (around 400 1309 
nm), minicells can be separated and purified from normal-sized cells by 1310 
employment of two successive buoyant density sucrose gradients. Purified 1311 
minicells can be stored with 10% glycerol at -70 ºC without loss of their 1312 
biological activity. Due to the abnormal chromosome segregation, minicells lack 1313 
chromosomal DNA; however, they are metabolically active and have all the 1314 
biochemical machinery to synthesize proteins. When a minicell-producing strain 1315 
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harbours a plasmid, these plasmids would segregate into the normal cells and 1316 
into the minicells. Thus, determination of de novo protein synthesis by minicells 1317 
has been successfully employed to characterize plasmid-encoded proteins, 1318 
including TAs (Lacks et al., 1986, Bravo et al., 1987, Bravo et al., 1988).  1319 
 1320 
 1321 
 1322 
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Table 1. Modes of action of some known antibioticsa 
 
Type Example / Representative Function inhibited 
β-Lactams Penicillins, cephalosporins Biosynthesis of bacterial cell wall 
Aminoglycosides Streptomycin
b
, Gentamicin Ribosomal-mediated protein translation 
Glycopeptides Vancomycin
c
 Cell wall biosynthesis 
Tetracyclines Tetracycline
b 
Ribosomal-mediated protein translation 
Macrolides Erythromycin Ribosomal-mediated protein translation 
Lincosamides Clindamycin Ribosomal-mediated protein translation 
Phenicols Chloramphenicol
b 
Ribosomal-mediated protein translation 
Quinolones Ciprofloxacin DNA gyrase 
Pyrimidines Trimethoprim C1 metabolism 
Sulfonamides Sulfamethoxazole
d 
C1 metabolism 
Rifamycins Rifampin RNA polymerase 
Cationic peptides Colistin Cell membrane biosynthesis 
a
 Adapted from [Davies, 2010 #4750] 
b
 Not widely used due to high resistant bacteria  
c
 Vancomycin was considered as the ‘last’ antibiotic. Mechanisms of resistance to this antibiotic was 
reported by [Walsh, 1996 #4751] 
d
 Hardly used due to low effectiveness 
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Table 2. Alternative strategies to tackle AbR 
 
Classical strategies Novel strategies 
 
Chemical derivatives of the known antibiotics  
 
Entirely novel antibiotics 
Alternation in the use of antibiotics 
 
Collateral sensitivity 
Biologic approaches 
- Phage therapy 
- Vaccines 
- Peptides 
 
Novel small molecules 
- Antivirulence 
- Antipersisters 
 
Search for essential genes as targets Search for novel targets 
- Virulence factors  
- TAs 
 
Change antibiotic treatment until new resistance 
appears 
Target the spread of AbR  
- Mobilome: conjugation inhibitors (COINS) 
 
--- Translational interactions among healthcare 
cadres 
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Table 3. The 12 superfamilies of Type II toxins 
 
Superfamilies according 
sequence similarity 
 
Modes of action 
 
RelE/ParE 
 
- RelE inhibits  translation by cleaving translating mRNAs 
[Christensen, 2001 #29] 
- ParE inhibits replication by hindering DNA-gyrase activity [Jiang, 
2002 #5] 
 
CcdB/MazF/Kid 
 
- CcdB inhibits replication by hindering DNA-gyrase activity [van 
Melderen, 2002 #4317] 
- MazF/Kid inhibits translation by cleaving free mRNAs [Zhang, 
2003 #53] 
 
Doc 
 
Inhibition of translation by phosphorylating the translation 
elongation factor EF-Tu [Castro-Roa, 2013 #4557] 
 
Zeta 
 
Inhibition of peptidoglycan synthesis by phosphorylating the 
peptidoglycan precursor uridine diphosphate-N-acetylglucosamin 
[Mutschler, 2011 #3597] 
 
VapC 
 
Inhibition of translation by cleaving tRNA
fMet
 in the anticodon stem-
loop [Winther, 2011 #3641] 
 
HipA 
 
Inhibition of translation by hindering aminoacyl-tRNA synthetase 
[Germain, 2013 #4561] 
 
YafO 
 
Inhibition of translation by association with 50S ribosomal subunit 
[Zhang, 2009 #3720] 
 
VapD 
 
Inhibition of translation by cleaving free mRNAs [Kwon, 2012 
#4334] 
 
GinA 
 
Inhibition of translation
a
 [Leplae, 2011 #2223] 
GinB 
 
Inhibition of translation
a
 [Leplae, 2011 #2223] 
GinC 
 
Inhibition of translation
a
 [Leplae, 2011 #2223] 
GinD 
 
Inhibition of translation
a
 [Leplae, 2011 #2223] 
a 
Target not determined 
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Figure 2  
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Figure 3a  
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Figure 3b  
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Figure 4  
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Figure 5  
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Figure 6  
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